Clinical trial
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With…
NCT00313287 · Bukwang Pharmaceutical, Industry · Terminated
Key facts
| NCT number | NCT00313287 |
|---|---|
| Title | Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV |
| Official title | A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine 30 mg QD in Patients Chronically Infected With Hepatitis B Virus |
| Lead sponsor | Bukwang Pharmaceutical, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | clevudine |
| Enrollment | 180 |
| Start date | Jun 1, 2003 |
| Completion | Nov 1, 2004 |
| First posted | Apr 12, 2006 |
| Last update posted | Feb 1, 2017 |
| Countries | South Korea |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: